Nidal Al‐Huniti
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Lung Cancer Treatments and Mutations, Pharmaceutical studies and practices, Statistical Methods in Clinical Trials, Cancer Genomics and Diagnostics
Most-Cited Works
- → Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics(2016)370 cited
- → The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)(2018)115 cited
- → Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model(2018)108 cited
- → Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects(2008)99 cited
- → Hypercholesterolemia is a Potential Risk Factor for Asthma(2006)92 cited
- → Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children(2016)84 cited
- → Asthma and Insulin Resistance in Morbidly Obese Children and Adolescents(2007)82 cited
- → Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children(2017)75 cited
- → Single‐dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects(2009)50 cited
- → Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach(2019)46 cited